Amgen has reported that Repatha, or evolocumab, reduced the risk of death by 20% among high-risk adults who had never experienced a heart attack or stroke, adding a mortality signal to an already important cardiovascular-outcomes trial. The finding comes from a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial involving more than 12,000 patients and was presented at the European Society of Cardiology Congress 2026 alongside publication in Circulation. The mortality difference began emerging after approximately 18 months and continued during a median 4.6 years of follow-up.
The analysis matters because cardiovascular prevention has traditionally intensified after something bad happens. A patient has a myocardial infarction, survives a stroke or undergoes a revascularization procedure, and clinicians then become more aggressive about reducing low-density lipoprotein cholesterol. VESALIUS-CV asks whether high-risk patients could avoid that transition by lowering LDL cholesterol intensively before the first major event occurs.
What did VESALIUS-CV already show before the new mortality analysis?
The original Phase 3 results had already established a significant cardiovascular benefit.
Repatha reduced the risk of the primary three-component major adverse cardiovascular event endpoint, comprising coronary heart disease death, myocardial infarction or ischemic stroke, by 25% compared with placebo when added to optimized lipid-lowering therapy. A broader four-component endpoint that also included ischemia-driven arterial revascularization fell by 19%, while the risk of myocardial infarction fell by 36%.
The new August 31 analysis extends those findings into mortality. Amgen reported a 20% reduction in the risk of death from any cause and said cardiovascular mortality was also meaningfully reduced. Because mortality was evaluated in a prespecified secondary analysis rather than serving as the original primary endpoint, that statistical hierarchy should remain clear when interpreting the finding.
The overall evidence nevertheless becomes more compelling when event prevention and mortality move in the same direction.
Who were the patients in the Repatha VESALIUS-CV trial?
VESALIUS-CV studied patients at substantial cardiovascular risk who had not yet suffered a myocardial infarction or stroke.
Participants had known atherosclerotic cardiovascular disease or high-risk diabetes and elevated atherogenic lipid measurements despite receiving the highest tolerated statin dose, ezetimibe or other optimized lipid-lowering therapy. Median baseline LDL cholesterol was approximately 122 mg/dL.
More than 12,000 patients were randomized to Repatha or placebo in addition to background therapy.
In a lipid substudy, median LDL cholesterol among observed Repatha recipients reached approximately 45 mg/dL compared with 109 mg/dL in the placebo group.
That large difference makes VESALIUS-CV another important test of the longstanding LDL hypothesis: when atherogenic cholesterol is pushed substantially lower, does clinical cardiovascular risk keep falling?
How does Repatha lower LDL cholesterol?
Repatha is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, better known as PCSK9.
PCSK9 normally binds to LDL receptors and promotes their degradation. Those receptors are responsible for removing LDL particles from circulation.
By preventing PCSK9 from destroying LDL receptors, evolocumab allows more receptors to return to the liver-cell surface, increasing the liver’s ability to clear LDL cholesterol from blood.
The mechanism can produce much larger LDL reductions than statins alone, which is why PCSK9 inhibitors are particularly relevant for patients who remain above cholesterol targets despite conventional therapy.
The remaining challenge has historically been identifying which high-risk patients justify escalation to an injectable biologic before they have suffered their first major cardiovascular event.
Why is preventing the first heart attack different from preventing the second?
A first cardiovascular event can permanently change a patient’s life.
A myocardial infarction can damage heart muscle and create chronic heart failure risk. A stroke can produce lasting neurological disability. Even a patient who survives and appears to recover can move into a much higher-risk category for recurrent events.
That means “primary prevention” among genuinely high-risk people is not merely about postponing a medical event on a chart. It is about preventing a biological transition from high risk to established irreversible damage.
Amgen’s additional analyses found that evolocumab reduced not only first events but also subsequent and total cardiovascular events. The company also reported that myocardial-infarction reduction was apparent as early as six months and was driven particularly by type 1 plaque-rupture heart attacks and larger infarctions.
That pattern helps explain why a mortality difference could emerge over longer follow-up.
Does this mean everyone with high cholesterol should receive Repatha?
No.
VESALIUS-CV involved a specifically selected high-risk population rather than every person with elevated LDL cholesterol. Statins remain foundational cholesterol-lowering medicines because of their extensive evidence base, oral dosing, low cost and broad accessibility.
Ezetimibe and other therapies can also be used before or alongside PCSK9 inhibition depending on the patient.
The trial instead strengthens the case for identifying people whose absolute cardiovascular risk is high enough that waiting for the first heart attack or stroke before intensifying therapy may represent a missed prevention opportunity.
Cost, injection preference, baseline LDL cholesterol, previous treatment, diabetes, established coronary or peripheral artery disease and overall cardiovascular risk all influence the decision.
How could VESALIUS-CV affect cholesterol-treatment guidelines?
The trial creates pressure to rethink the line separating primary and secondary prevention.
Traditional terminology can make everyone without a previous heart attack or stroke sound relatively healthy. In reality, a patient can have extensive coronary atherosclerosis, peripheral artery disease, diabetes and markedly elevated LDL while technically remaining in a “no prior MI or stroke” category.
VESALIUS-CV shows that this high-risk group can derive meaningful event reduction from intensive PCSK9-mediated LDL lowering. The latest mortality analysis increases the clinical relevance because physicians are no longer discussing only a surrogate cholesterol number or even nonfatal events.
Guideline committees will still need to determine where evolocumab fits relative to statins, ezetimibe and newer lipid therapies, including emerging drugs targeting lipoprotein(a).
Why is the 20% mortality finding important but worth describing carefully?
Because secondary analyses can become exaggerated in headlines.
The mortality assessment was prespecified, which makes it more credible than an unplanned post hoc search through the data, but the original trial was principally designed around major cardiovascular-event endpoints. It would therefore be misleading to imply that VESALIUS-CV was originally powered solely as a mortality trial.
The appropriate interpretation is stronger and more useful: a large randomized trial already demonstrated fewer first major cardiovascular events with evolocumab, and a prespecified follow-up analysis now shows a meaningful mortality reduction consistent with that broader benefit.
What should cardiologists watch next after VESALIUS-CV?
The practical question now shifts from whether intensive LDL lowering works to how early healthcare systems can identify the patients who need it.
Real-world analyses presented alongside VESALIUS-CV suggest that many high-risk patients remain undertreated and fail to reach recommended LDL targets. Amgen also reported sex differences, with high-risk women without previous myocardial infarction or stroke less likely than men to receive intensive lipid-lowering therapy or achieve LDL goals.
That creates a familiar gap between clinical-trial evidence and routine care.
Repatha’s newest data therefore tell two stories. The scientific story is that aggressively reducing LDL cholesterol before a first heart attack or stroke can prevent events and may reduce mortality. The healthcare-delivery story is harder: finding those high-risk people early enough and getting them onto appropriate treatment before their first cardiovascular event announces that they were high risk all along.
